Stomach perforation-induced general occlusion/occlusion-like syndrome and stable gastric pentadecapeptide BPC 157 therapy effect

Figure 1 Stomach illustrative presentation. A and E: Before procedure; B and F: After perforation before therapy; C and D: Course after given therapy into the perforated defect, saline; G and H: BPC 157. Control rats: (1) Before procedure (normal rats, A); (2) after perforation before therapy application (B); (3) after saline application (1 mL/rat into the perforated defect in the stomach) (C and D), immediately thereafter (C); and (4) later (at 5 min following medication, D). BPC 157 rats: (1) Stomach before perforation (normal rats, E); (2) after perforation, but before BPC 157 therapy application (F), and (3) specifically after BPC 157 application (10 µg or 10 ng/kg, 1 mL/rat into the perforated defect in the stomach, G and H), immediately thereafter (G), and later (at 5 min following medication, H).